Page 4 - Pharmaceutical Firms

Trump tariff on Indian goods to raise drugs costs in US: Pharmexcil

Pharmaceuticals Export Promotion Council of India (Pharmexcil) on Thursday said President Donald Trump's imposition of a 25 per cent tariff plus unspecified penalty on all goods coming from India starting August 1, will result in increased costs for essential drugs in the US, ultimately harming consumers and healthcare systems in the country in the long term. The US market, heavily reliant on India for Active Pharmaceutical Ingredients (APIs) and low-cost generics, faces a daunting challenge in finding alternative sources that can match the scale, quality, and affordability that India offers, Pharmexcil Chairman Namit Joshi said in a statement. President Donald Trump on Wednesday announced the imposition of a 25 per cent tariff on all goods coming from India starting August 1, plus an unspecified penalty for buying Russian crude oil and military equipment. Reacting to the development, Joshi said India has long been a cornerstone of the global supply chain for affordable, high-qualit

US CDMO business seeing softening, says Piramal Pharma Chairperson

US biotech funding slowdown hits Piramal's CDMO business as company expands sterile injectables facility and maintains long-term growth targets

Torrent Pharma Q1 results: PAT up 20% on robust sales across territories

Torrent Pharmaceuticals reports Rs 548 crore Q1 net profit, led by strong growth in India, the US, and Brazil, with chronic therapies and top brands driving momentum

Results preview: Pharma firms stare at muted earnings growth for Q1

Indian pharma firms are set to post modest Q1FY26 earnings, with Revlimid erosion impacting US revenues and domestic growth moderating in chronic therapies

Blue Jet Healthcare shares drop 10% post Q1 results; details here

At 2:30 PM, shares of Blue Jet Healthcare were trading at ₹906.15, down by 10 per cent on the BSE.

Sun Pharma's psoriasis drug delivers positive results in arthritis trials

Phase 3 trials show ILUMYA improved PsA symptoms significantly, with no new safety concerns; results support potential regulatory submissions in the US and globally

CORONA Remedies acquires 7 pharma brands from Bayer India, plans expansion

CORONA Remedies deepens footprint in women's healthcare and cardiology with Bayer India portfolio acquisition, entering anti-platelet and hormone therapy segments

CDSCO extends COPP application deadline for pharma units to August 15

Pharma firms get time till August 15 to file COPP applications online via ONDLS as CDSCO addresses onboarding challenges and industry pleas

PL Capital bets on domestic sectors, sees 6.5% Nifty growth in 12 months

PL Capital expects pharma, banks, defence, and staples to outperform in the near term as domestic demand revives

Generic glut leads to numerous price actions on diabetes medications

Government may fix retail prices for empagliflozin combinations as generic versions flood the market following the drug's patent expiry, causing price drops

Sun Pharma gains on US launch of Leqselvi, analysts see strong upside

Sun Pharma rises 2.7% as it launches Leqselvi in US following settlement with Incyte, with analysts projecting $200-300 million revenue from the drug in 3-5 years

Sun Pharma shares rise 2% on US launch of hair loss drug after settlement

Sun Pharma shares rose nearly 2 per cent on Tuesday after the company launched Leqselvi, a new treatment for severe alopecia areata

Sun Pharma launches Leqselvi in US after patent settlement with Incyte Corp

Sun Pharma will pay Incyte an upfront fee and royalties to market Leqselvi in the US for alopecia areata until patent expiry in FY26 following a litigation settlement

Mukul Agrawal portfolio pharmaceutical stock surges 10% in weak market

Shares of Neuland Laboratories rallied 10 per cent to ₹13,500 on the BSE in Monday's intra-day trade in otherwise a subdued market.

Wockhardt shares rise 2% after exiting US generics business

Wockhardt shares rose 2 per cent after it decided to exit the US generic pharmaceutical segment after incurring consistent losses

Asston Pharmaceuticals IPO booked 173x; check allotment, GMP, listing date

Asston Pharmaceuticals IPO allotment status: Investors can check their status on the official websites of BSE and Maashitla Securities

Nectar to sell API, formulations and menthol biz to Ceph for ₹1,290 cr

Nectar Lifesciences Ltd on Tuesday said it will sell its active pharmaceutical ingredients and formulation along with menthol business assets to Ceph Lifesciences Pvt Ltd, for Rs 1,290 crore. The company has signed a definitive Business Transfer Agreement (BTA) for the sale of its core business division, comprising the manufacture, distribution, and marketing of Active Pharmaceutical Ingredients (APIs) and formulations to Ceph Lifesciences for Rs 1,270 crore on a slump sale basis, Nectar said in a regulatory filing. Additionally, the company has entered into an Asset Purchase Agreement (APA) for the sale of its menthol business assets to Ceph Lifesciences for Rs 20 crore, marking a comprehensive restructuring move aligned with its future strategy, it added. "By divesting mature segments of our business, we are laying the foundation for a focused and agile organisation geared towards innovation and long-term value creation," Nectar Lifesciences Promoter and Chairman Sanjiv Goyal ...

Are generic medicines as good as branded ones? Here's what you should know

Are cheaper generic medicines really as good as expensive branded ones? Here's what doctors and pharma experts say about quality, safety, and trust

Emcure Pharma shares dip after 2.4% stake change hands in block trades

Emcure Pharma shares fell after about 4.53 million shares, or a 2.4 per cent stake, changed hands via block trades on the NSE

Laurus Labs nears record high after 4 years, zooms 84% from 52-week low

Laurus Labs management sees a clear pathway for further margin expansion as the company continue delivering on mid-late phase projects, ramping up new assets, and better asset utilisation.